Last reviewed · How we verify
Baminercept alfa 4
Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors.
Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | Baminercept alfa 4 |
|---|---|
| Also known as | BG9924, LT beta |
| Sponsor | Biogen |
| Drug class | TNF inhibitor |
| Target | TNF |
| Modality | Biologic |
| Therapeutic area | Rheumatology |
| Phase | Phase 2 |
Mechanism of action
This mechanism of action is based on the principle of blocking the pro-inflammatory effects of TNF, a cytokine involved in systemic inflammation and one of the cytokines that make up the acute phase reaction, which is part of the initial immune response.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Muscle pain
- Nausea
Key clinical trials
- 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (PHASE2)
- Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baminercept alfa 4 CI brief — competitive landscape report
- Baminercept alfa 4 updates RSS · CI watch RSS
- Biogen portfolio CI